Opportunity Information: Apply for PAR 10 048
Apply for PAR 10 048
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Development of Multifunctional Drug and Gene Delivery Systems (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.394 Cancer Detection and Diagnosis Research 93.396 Cancer Biology Research.
- This funding opportunity was created on Dec 7, 2009 and posted on Dec 7, 2009.
- Applicants must submit their applications by Jan 7, 2013. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Small businesses Others (see text field entitled Additional Information on Eligibility for clarification) County governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education For profit organizations other than small businesses Public housing authorities/Indian housing authorities Private institutions of higher education Independent school districts Native American tribal organizations (other than Federally recognized tribal governments) City or township governments Special district governments State governments Native American tribal governments (Federally recognized) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Public and State controlled institutions of higher education.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The NIH Funding Opportunity Announcement PAR-10-048, titled "Development of Multifunctional Drug and Gene Delivery Systems (R01)," supports research projects aimed at creating next-generation delivery platforms that do more than just carry a therapeutic payload. The core idea is to engineer novel, multifunctional systems for drug and gene delivery that can (1) target specific cells and even specific compartments inside cells, and (2) actively track what happens after administration by building imaging and/or sensing capabilities directly into the delivery system. In practical terms, NIH is looking for delivery technologies that can help answer real-time questions such as whether a therapy reached the intended biological destination, how much actually got there, and whether it is producing a measurable therapeutic effect.
This opportunity is sponsored by two NIH institutes: the National Institute of Biomedical Imaging and Bioengineering (NIBIB) and the National Heart, Lung, and Blood Institute (NHLBI). It uses the standard NIH Research Project Grant (R01) mechanism, meaning it is designed for hypothesis-driven or technology-driven research with clear aims, milestones, and rigorous evaluation. A key expectation is that applicants propose to develop at least one prototype multifunctional delivery system by the end of the project period, so the program is not limited to early conceptual work; it is meant to push teams toward an integrated, testable delivery-and-monitoring platform.
Because the scientific goals sit at the intersection of multiple specialties, the FOA explicitly expects multidisciplinary teams. Applications should include investigators with strong expertise in both drug/gene delivery and imaging (or sensing) technologies. NIH also strongly encourages the Multi-PD/PI (multiple principal investigator) model as a straightforward way to reflect and manage the required cross-disciplinary leadership. The underlying message is that a competitive application will not treat imaging as an afterthought or add-on, but will tightly integrate imaging/sensing design decisions with delivery chemistry, materials, targeting strategy, and biological performance.
Budget size, project duration, and the number of awards are not fixed in the announcement. Awards depend on available funds, and NIH anticipates that funding levels will vary based on the scope and cost structure of each proposed project. In other words, there is no single standard award amount described here; NIH will make funding decisions based on application quality, the proposed period of support, and the requested costs relative to what is justified by the work.
Eligibility is broad and includes many organization types: higher education institutions (public and private), nonprofit and for-profit entities (including small businesses), state and local governments, tribal governments and tribal organizations, U.S. territories, and other entities described in the eligibility section. The FOA also lists a range of institution types that are explicitly recognized as eligible, including HBCUs, Hispanic-serving institutions, tribally controlled colleges and universities, Alaska Native and Native Hawaiian Serving Institutions, faith-based or community-based organizations, and even non-U.S. (foreign) organizations and regional organizations. There is no cost sharing or matching requirement.
From an administrative standpoint, the opportunity is categorized as a discretionary grant, posted December 7, 2009, with an original and current closing date listed as January 7, 2013, and an archive date of February 7, 2013, indicating it is no longer active as a current submission route. The CFDA numbers associated with the listing are 93.394 (Cancer Detection and Diagnosis Research) and 93.396 (Cancer Biology Research), which signals relevance to cancer-related research areas, even though the sponsoring institutes named in the description are NIBIB and NHLBI. The full archived announcement is referenced via the NIH Grants Guide link: http://grants.nih.gov/grants/guide/pa-files/PAR-10-048.html. For access or technical issues with the posting, the contact provided is the NIH Office of Extramural Research (OER) Webmaster at FBOWebmaster@OD.NIH.GOV.
Overall, the FOA is essentially a call for integrated therapeutic delivery systems that combine targeted delivery (including intracellular targeting), built-in monitoring through imaging or sensing, and a clear path to a functional prototype within the R01 project period, led by a genuinely cross-disciplinary team that spans delivery science and imaging technology.
FAQs: NIH PAR-10-048 - Development of Multifunctional Drug and Gene Delivery Systems (R01)
What is PAR-10-048?
PAR-10-048 is an NIH Funding Opportunity Announcement (FOA) titled "Development of Multifunctional Drug and Gene Delivery Systems (R01)." It supports R01 research projects focused on building next-generation delivery platforms for drugs and genes that combine targeted delivery with built-in imaging and/or sensing functions.
What is the main goal of this FOA?
The main goal is to engineer multifunctional drug and gene delivery systems that do more than transport a therapeutic payload. The delivery system is expected to (1) target specific cells and even specific intracellular compartments, and (2) track what happens after administration using integrated imaging and/or sensing so researchers can measure where the therapy goes, how much arrives, and whether it is producing a measurable effect.
What does "multifunctional" mean in this announcement?
In this FOA, "multifunctional" refers to delivery systems that combine targeting capabilities with imaging and/or sensing capabilities within the same integrated platform, rather than treating imaging as a separate add-on.
What kinds of research questions are these delivery systems expected to help answer?
The FOA emphasizes real-time or post-administration questions such as whether the therapy reached the intended biological destination, how much of it got there, and whether it is producing a measurable therapeutic effect based on built-in monitoring.
Does the FOA focus on drug delivery, gene delivery, or both?
Both. The FOA specifically calls for "drug and gene delivery systems," and the intent is to support platforms applicable to therapeutic payload delivery with integrated tracking via imaging and/or sensing.
Is targeting limited to specific tissues, or does it include intracellular targeting?
The FOA explicitly includes both targeting to specific cells and targeting to specific compartments inside cells (intracellular targeting).
What is the required grant mechanism?
The FOA uses the standard NIH Research Project Grant (R01) mechanism, intended for hypothesis-driven or technology-driven research with clear aims, milestones, and rigorous evaluation.
Is NIH expecting a working prototype by the end of the project?
Yes. A key expectation stated in the FOA is that applicants propose to develop at least one prototype multifunctional delivery system by the end of the project period, signaling that the program is meant to move beyond early concepts toward an integrated, testable platform.
Is this funding intended for early conceptual work only?
No. While fundamental research can be part of the approach, the FOA is not limited to early conceptual work and explicitly pushes teams toward developing an integrated delivery-and-monitoring prototype.
Which NIH institutes sponsor this FOA?
The sponsoring institutes named are the National Institute of Biomedical Imaging and Bioengineering (NIBIB) and the National Heart, Lung, and Blood Institute (NHLBI).
What team structure does NIH expect for competitive applications?
The FOA explicitly expects multidisciplinary teams. Applications should include investigators with strong expertise in both drug/gene delivery and imaging (or sensing) technologies, with imaging/sensing tightly integrated into the delivery system design.
Is the Multi-PD/PI model allowed or encouraged?
It is strongly encouraged. The FOA highlights the Multi-PD/PI (multiple principal investigator) model as a straightforward way to reflect and manage cross-disciplinary leadership.
Can imaging be included as a secondary component or add-on?
The FOA signals that imaging/sensing should not be treated as an afterthought. A competitive application is expected to integrate imaging/sensing design decisions with delivery chemistry, materials, targeting strategy, and biological performance.
Are budget size, project duration, or number of awards specified?
No. The FOA does not fix the budget size, project duration, or number of awards. Awards depend on available funds, and NIH anticipates funding levels will vary based on the scope and cost structure of each proposed project.
How does NIH decide the award amount if no standard budget is listed?
Based on the information provided, NIH funding decisions are tied to application quality, the proposed period of support, and whether the requested costs are justified by the work.
Is cost sharing or matching required?
No. The FOA states there is no cost sharing or matching requirement.
Who is eligible to apply?
Eligibility is broad. The FOA includes higher education institutions (public and private), nonprofit and for-profit entities (including small businesses), state and local governments, tribal governments and tribal organizations, U.S. territories, and other entities described in the eligibility section.
Are minority-serving institutions included as eligible applicants?
Yes. The FOA explicitly recognizes eligibility for institution types such as HBCUs, Hispanic-serving institutions, tribally controlled colleges and universities, Alaska Native and Native Hawaiian Serving Institutions, and faith-based or community-based organizations.
Are non-U.S. organizations eligible?
Yes. The FOA indicates that non-U.S. (foreign) organizations and regional organizations are included among eligible applicants.
What type of grant is this classified as?
It is categorized as a discretionary grant.
When was the opportunity posted, and what are the closing and archive dates?
The FOA was posted on December 7, 2009. The original and current closing date listed is January 7, 2013, and the archive date is February 7, 2013.
Is PAR-10-048 still active for submission?
No. Based on the listed closing date and archive date, it is no longer active as a current submission route.
What CFDA numbers are associated with this listing?
The CFDA numbers listed are 93.394 (Cancer Detection and Diagnosis Research) and 93.396 (Cancer Biology Research).
Do the CFDA numbers imply a cancer research connection?
Yes. The CFDA numbers cited correspond to cancer-related research areas, signaling relevance to cancer detection/diagnosis and cancer biology research, even though the sponsoring institutes named in the description are NIBIB and NHLBI.
Where can I find the full archived FOA text?
The archived announcement is referenced via the NIH Grants Guide at: http://grants.nih.gov/grants/guide/pa-files/PAR-10-048.html.
Who should be contacted for access or technical issues related to the posting?
For access or technical issues with the posting, the contact provided is the NIH Office of Extramural Research (OER) Webmaster at FBOWebmaster@OD.NIH.GOV.
What is the overall takeaway for applicants based on the FOA description?
The FOA is a call for integrated drug/gene delivery systems that combine targeted delivery (including intracellular targeting) with built-in monitoring through imaging or sensing, and that have a clear path to at least one functional prototype within the R01 project period, led by a genuinely cross-disciplinary team spanning delivery science and imaging technology.
Browse more opportunities from the same category: Education Health
Next opportunity: Cooperative Ecosystem Studies Unit, Piedmont South Atlantic CESU
Previous opportunity: Supporting Democracy, Good Governance, and National Reconciliation
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 10 048
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 10 048) also looked into and applied for these:
| Funding Opportunity |
|---|
| Cognitive Remediation Approaches to Improve Drug Abuse Treatment Outcomes (R01) Apply for RFA DA 10 006 Funding Number: RFA DA 10 006 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Cognitive Remediation Approaches to Improve Drug Abuse Treatment Outcomes (R21) Apply for RFA DA 10 007 Funding Number: RFA DA 10 007 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Academic Career Award (Parent K07) Apply for PA 10 058 Funding Number: PA 10 058 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Pre Application for the 2010 NIDA Avant Garde Award Program for HIV/AIDS Research (X02) Apply for PAR 10 068 Funding Number: PAR 10 068 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| 2010 NIDA Avant Garde Award Program for HIV/AIDS Research (DP1) Apply for RFA DA 10 012 Funding Number: RFA DA 10 012 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| AIDS Malignancy Clinical Trials Consortium (Limited Competition U01) Apply for RFA CA 10 502 Funding Number: RFA CA 10 502 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Mechanism for Time Sensitive Drug Abuse Research (R01) Apply for PAR 10 072 Funding Number: PAR 10 072 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| SBIR Phase II Bridge Awards to Accelerate the Development of Cancer Therapeutics, Imaging Technologies, Interventional Devices, Diagnostics, and Prognostics toward Commercialization (R44) Apply for RFA CA 10 009 Funding Number: RFA CA 10 009 Agency: National Institutes of Health Category: Education Health Funding Amount: $1,000,000 |
| Image Guided Cancer Interventions (SBIR R43/R44) Apply for PA 10 079 Funding Number: PA 10 079 Agency: National Institutes of Health Category: Education Health Funding Amount: $100,000 |
| Image Guided Cancer Interventions (STTR R41/R42) Apply for PA 10 080 Funding Number: PA 10 080 Agency: National Institutes of Health Category: Education Health Funding Amount: $100,000 |
| Shared Instrumentation Grant Program (S10) Apply for PAR 10 082 Funding Number: PAR 10 082 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Systems Biology, HIV/AIDS, and Substance Abuse (R01) Apply for RFA DA 10 014 Funding Number: RFA DA 10 014 Agency: National Institutes of Health Category: Education Health Funding Amount: $750,000 |
| Pre Application for the 2010 NIDA Translational Avant Garde Award for Medication Development for Diseases of Addiction (X02) Apply for PAR 10 095 Funding Number: PAR 10 095 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| 2010 NIDA Translational Avant Garde Award for Medication Development for Diseases of Addiction (DP1) Apply for RFA DA 10 013 Funding Number: RFA DA 10 013 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Medications Development for Substance Related Disorders (R01) Apply for RFA DA 10 018 Funding Number: RFA DA 10 018 Agency: National Institutes of Health Category: Education Health Funding Amount: $1,000,000 |
| Deep Sequencing and Analysis of Pharmacogenomic Regions Discovery and Analysis of Genetic Variants Contributing to Drug Abuse and Addiction (R01) Apply for RFA DA 10 019 Funding Number: RFA DA 10 019 Agency: National Institutes of Health Category: Education Health Funding Amount: $250,000 |
| Institutional Clinical and Translational Science Award (U54) Apply for RFA RM 10 001 Funding Number: RFA RM 10 001 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Technology Based Adherence Interventions for Substance Abusing Populations with HIV (R01) Apply for PAS 10 097 Funding Number: PAS 10 097 Agency: National Institutes of Health Category: Education Health Funding Amount: $250,000 |
| Technology Based Adherence Interventions for Substance Abusing Populations with HIV (R34) Apply for PAS 10 098 Funding Number: PAS 10 098 Agency: National Institutes of Health Category: Education Health Funding Amount: $250,000 |
| Chronic Co Morbid Conditions in HIV U.S. Adults on Highly Effective Anti Retroviral Therapy (R01) Apply for RFA NR 10 001 Funding Number: RFA NR 10 001 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 10 048", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.